XML 20 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue
 9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Net product revenue$6,189.0 $5,281.1 $18,579.5 $15,762.3 
Collaboration and other revenue (1)
583.8 459.5 1,739.0 1,337.5 
Revenue$6,772.8 $5,740.6 $20,318.5 $17,099.8 
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $62.1 million and $136.1 million during the three and nine months ended September 30, 2021, respectively, and $31.5 million and $101.5 million during the three and nine months ended September 30, 2020, respectively.
We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to certain of our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance® and Trajenta® families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.
Adjustments to Revenue
Adjustments to increase (decrease) revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than 1 percent of U.S. revenue during each of the three and nine months ended September 30, 2021, and approximately (1) percent and 1 percent of U.S. revenue for the three and nine months ended September 30, 2020, respectively.
Contract Liabilities
Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract.
The following table summarizes contract liability balances:
 September 30, 2021December 31, 2020
Contract liabilities$278.4 $276.8 
During the three and nine months ended September 30, 2021 and 2020, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.
Disaggregation of Revenue
The following table summarizes revenue by product for the three months ended September 30, 2021 and 2020:
Three Months Ended September 30,
 20212020
U.S.
Outside U.S.Total
U.S.
Outside U.S.Total
Revenue—to unaffiliated customers:
Diabetes:
Trulicity®
$1,201.4 $398.8 $1,600.1 $791.2 $315.4 $1,106.6 
Humalog® (1)
347.3 279.4 626.7 390.1 266.9 656.9 
Jardiance (2)
221.2 169.2 390.4 163.3 147.5 310.8 
Humulin®
193.4 93.4 286.7 214.0 91.9 305.9 
Basaglar®
114.7 78.1 192.8 178.5 69.7 248.2 
Other Diabetes65.0 112.2 177.4 61.4 93.1 154.6 
Total Diabetes2,143.0 1,131.1 3,274.1 1,798.5 984.5 2,783.0 
Oncology:
Alimta®
297.2 159.8 457.0 291.9 286.1 578.0 
Verzenio®
199.6 135.9 335.5 158.9 75.5 234.4 
Cyramza®
84.8 168.6 253.4 94.5 158.2 252.7 
Erbitux®
114.0 20.3 134.3 122.5 14.0 136.4 
Tyvyt®
— 125.6 125.6 — 84.4 84.4 
Other Oncology35.3 65.1 100.3 14.7 32.7 47.5 
Total Oncology730.9 675.3 1,406.1 682.5 650.9 1,333.4 
Immunology:
Taltz®
422.2 170.9 593.1 326.2 128.3 454.5 
Olumiant® (3)
194.0 212.9 406.9 14.5 147.5 162.0 
Other Immunology— 4.9 4.9 6.1 4.5 10.6 
Total Immunology616.2 388.7 1,004.9 346.8 280.3 627.1 
Neuroscience:
Emgality®
99.9 40.1 140.0 81.4 10.1 91.5 
Cymbalta®
7.0 125.1 132.0 11.1 175.5 186.6 
Zyprexa®
13.0 88.7 101.7 21.2 91.5 112.7 
Other Neuroscience24.7 51.6 76.5 26.7 53.2 79.9 
Total Neuroscience144.6 305.5 450.2 140.4 330.3 470.7 
Other:
COVID-19 Antibodies (4)
215.5 1.6 217.1 — — — 
Forteo®
109.6 91.3 200.9 144.6 122.3 266.9 
Cialis®
(6.5)137.4 130.9 15.1 147.3 162.5 
Other36.3 52.4 88.8 33.5 63.6 97.0 
Total Other354.9 282.7 637.7 193.2 333.2 526.4 
Revenue$3,989.6 $2,783.3 $6,772.8 $3,161.4 $2,579.3 $5,740.6 
Numbers may not add due to rounding.
(1) Humalog revenue includes insulin lispro.
(2) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.
(3) Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA).
(4) COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs.
The following table summarizes revenue by product for the nine months ended September 30, 2021 and 2020:
Nine Months Ended September 30,
 20212020
U.S. Outside U.S.TotalU.S.Outside U.S.Total
Revenue—to unaffiliated customers:
Diabetes:
Trulicity$3,465.7 $1,122.5 $4,588.2 $2,673.2 $892.5 $3,565.7 
Humalog (1)
1,009.0 842.3 1,851.3 1,070.4 837.4 1,907.8 
Jardiance (2)
566.8 492.1 1,058.9 453.0 387.3 840.3 
Humulin633.5 290.3 923.8 642.5 292.7 935.2 
Basaglar423.3 226.8 650.1 638.7 203.7 842.3 
Other Diabetes185.7 302.6 488.3 185.2 254.4 439.6 
Total Diabetes6,284.0 3,276.6 9,560.6 5,663.0 2,868.0 8,530.9 
Oncology:
Alimta911.9 714.7 1,626.6 933.4 743.8 1,677.2 
Verzenio582.1 363.7 945.8 430.0 201.1 631.1 
Cyramza266.3 496.3 762.5 277.6 470.8 748.4 
Erbitux357.7 45.9 403.7 356.1 40.6 396.7 
Tyvyt— 340.2 340.2 — 205.9 205.9 
Other Oncology83.7 169.9 253.6 26.0 118.2 144.2 
Total Oncology2,201.7 2,130.7 4,332.4 2,023.1 1,780.4 3,803.5 
Immunology:
Taltz1,071.6 493.8 1,565.4 942.9 350.3 1,293.2 
Olumiant (3)
236.5 572.6 809.1 39.0 407.7 446.7 
Other Immunology15.2 14.5 29.7 13.2 8.1 21.3 
Total Immunology1,323.3 1,080.9 2,404.2 995.1 766.1 1,761.2 
Neuroscience:
Cymbalta30.3 454.0 484.3 30.5 546.5 576.9 
Emgality313.5 102.2 415.7 229.3 23.6 252.9 
Zyprexa28.3 264.5 292.8 41.5 266.2 307.7 
Other Neuroscience81.0 154.0 235.0 53.4 165.7 219.2 
Total Neuroscience453.1 974.7 1,427.8 354.7 1,002.0 1,356.7 
Other:
COVID-19 Antibodies (4)
949.5 226.7 1,176.2— — — 
Forteo330.1 287.7 617.8 386.7 405.2 791.9 
Cialis(3.1)541.8 538.7 64.6 421.6 486.2 
Other96.5 164.3 260.8 144.2 225.2 369.4 
Total Other1,373.0 1,220.5 2,593.5 595.5 1,052.0 1,647.5 
Revenue$11,635.1 $8,683.4 $20,318.5 $9,631.4 $7,468.5 $17,099.8 
Numbers may not add due to rounding.
(1) Humalog revenue includes insulin lispro.
(2) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.
(3) Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to EUA.
(4) COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs.
The following table summarizes revenue by geographical area:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Revenue—to unaffiliated customers (1):
U.S.$3,989.6 $3,161.4 $11,635.1 $9,631.4 
Europe1,098.6 1,046.7 3,629.6 2,984.4 
Japan595.0 660.1 1,832.2 1,919.1 
China400.3 289.1 1,285.0 796.2 
Other foreign countries689.4 583.2 1,936.7 1,768.7 
Revenue$6,772.8 $5,740.6 $20,318.5 $17,099.8 
Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer.